Ariceum doses first patient with satoreotide
The treatment targets extensive stage small cell lung cancer and aims to boost therapeutic impact
Read More
Tag: dose
First dose completed in phase 1 cannabinoid study
OCTP aims to demonstrate the lead candidate’s safety, tolerability and pharmacokinetic profile
Read More
Delix Therapeutics completes dose study for DLX-001
During research there were not any clinically-relevant adverse events or psychotomimetic effects
Read More
Avacta announces AVA6000 dose escalation results
Candidate is a cancer therapy that has been chemically modified with Avacta’s pre|CISION platform
Read More
Avacta doses first patient in pivotal phase 1a trial
Individual receives AVA6000 treatment as part of additional dose escalating study
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
